Published in Genome Med on March 27, 2012
DNA methylation age of human tissues and cell types. Genome Biol (2013) 7.48
Cancer as a dysregulated epigenome allowing cellular growth advantage at the expense of the host. Nat Rev Cancer (2013) 2.41
Age-associated epigenetic drift: implications, and a case of epigenetic thrift? Hum Mol Genet (2013) 1.76
A genome-wide methylation study on obesity: differential variability and differential methylation. Epigenetics (2013) 1.51
Cigarette smoking reduces DNA methylation levels at multiple genomic loci but the effect is partially reversible upon cessation. Epigenetics (2014) 1.47
Large-scale hypomethylated blocks associated with Epstein-Barr virus-induced B-cell immortalization. Genome Res (2013) 1.34
DNA methylation and healthy human aging. Aging Cell (2015) 1.27
Large hypomethylated blocks as a universal defining epigenetic alteration in human solid tumors. Genome Med (2014) 1.23
An integrative multi-scale analysis of the dynamic DNA methylation landscape in aging. PLoS Genet (2015) 1.13
Role of DNA methylation and epigenetic silencing of HAND2 in endometrial cancer development. PLoS Med (2013) 1.10
MethylPurify: tumor purity deconvolution and differential methylation detection from single tumor DNA methylomes. Genome Biol (2014) 1.09
Epigenetic modulators, modifiers and mediators in cancer aetiology and progression. Nat Rev Genet (2016) 1.07
Pan-cancer patterns of DNA methylation. Genome Med (2014) 1.02
The dynamics of DNA methylation covariation patterns in carcinogenesis. PLoS Comput Biol (2014) 0.96
Distinctive topology of age-associated epigenetic drift in the human interactome. Proc Natl Acad Sci U S A (2013) 0.94
A BRCA1-mutation associated DNA methylation signature in blood cells predicts sporadic breast cancer incidence and survival. Genome Med (2014) 0.93
DNA methylation outliers in normal breast tissue identify field defects that are enriched in cancer. Nat Commun (2016) 0.93
Discordance of DNA methylation variance between two accessible human tissues. Sci Rep (2015) 0.91
Enriched domain detector: a program for detection of wide genomic enrichment domains robust against local variations. Nucleic Acids Res (2014) 0.90
The meta-epigenomic structure of purified human stem cell populations is defined at cis-regulatory sequences. Nat Commun (2014) 0.89
Corruption of the intra-gene DNA methylation architecture is a hallmark of cancer. PLoS One (2013) 0.88
Pyrosequencing Evaluation of Widely Available Bisulfite Conversion Methods: Considerations for Application. Med Epigenet (2014) 0.84
Aberrant methylation of imprinted genes is associated with negative hormone receptor status in invasive breast cancer. Int J Cancer (2015) 0.83
Correlation of an epigenetic mitotic clock with cancer risk. Genome Biol (2016) 0.82
Inactive or moderately active human promoters are enriched for inter-individual epialleles. Genome Biol (2013) 0.82
On the potential of models for location and scale for genome-wide DNA methylation data. BMC Bioinformatics (2014) 0.81
Increased DNA methylation variability in type 1 diabetes across three immune effector cell types. Nat Commun (2016) 0.80
Phenotype prediction based on genome-wide DNA methylation data. BMC Bioinformatics (2014) 0.79
Gene Expression Signatures Based on Variability can Robustly Predict Tumor Progression and Prognosis. Cancer Inform (2015) 0.77
Establishment of a Strong Link Between Smoking and Cancer Pathogenesis through DNA Methylation Analysis. Sci Rep (2017) 0.76
Stochastic epigenetic outliers can define field defects in cancer. BMC Bioinformatics (2016) 0.76
DNA methylation in cancer: three decades of discovery. Genome Med (2014) 0.76
A Comparative Study of Tests for Homogeneity of Variances with Application to DNA Methylation Data. PLoS One (2015) 0.75
Genetic Determinants of Epigenetic Patterns: Providing Insight into Disease. Mol Med (2015) 0.75
Multiple network algorithm for epigenetic modules via the integration of genome-wide DNA methylation and gene expression data. BMC Bioinformatics (2017) 0.75
Genome-wide analysis of differential transcriptional and epigenetic variability across human immune cell types. Genome Biol (2017) 0.75
Integration of genetic and epigenetic markers for risk stratification: opportunities and challenges. Per Med (2016) 0.75
A polycomb-mediated epigenetic field defect precedes invasive cervical carcinoma. Oncotarget (2016) 0.75
Parenclitic Network Analysis of Methylation Data for Cancer Identification. PLoS One (2017) 0.75
Tumour biomarkers: homeostasis as a novel prognostic indicator. Open Biol (2016) 0.75
Differential DNA methylation and PM2.5 species in a 450K epigenome-wide association study. Epigenetics (2016) 0.75
Smoking is associated with hypermethylation of the APC 1A promoter in colorectal cancer: the ColoCare Study. J Pathol (2017) 0.75
Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A (2005) 167.46
Statistical significance for genomewide studies. Proc Natl Acad Sci U S A (2003) 88.64
Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res (2002) 76.95
Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol (1999) 40.46
Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science (2005) 39.06
Control of developmental regulators by Polycomb in human embryonic stem cells. Cell (2006) 28.21
Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell (2010) 16.12
CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet (2006) 13.63
Linking DNA methylation and histone modification: patterns and paradigms. Nat Rev Genet (2009) 12.08
Principles and challenges of genomewide DNA methylation analysis. Nat Rev Genet (2010) 10.71
The epigenetic progenitor origin of human cancer. Nat Rev Genet (2006) 9.65
Increased methylation variation in epigenetic domains across cancer types. Nat Genet (2011) 8.92
Comparison of Beta-value and M-value methods for quantifying methylation levels by microarray analysis. BMC Bioinformatics (2010) 7.78
Validation of a DNA methylation microarray for 450,000 CpG sites in the human genome. Epigenetics (2011) 7.38
Age-dependent DNA methylation of genes that are suppressed in stem cells is a hallmark of cancer. Genome Res (2010) 6.03
Cancer epigenetics reaches mainstream oncology. Nat Med (2011) 5.83
Human aging-associated DNA hypermethylation occurs preferentially at bivalent chromatin domains. Genome Res (2010) 5.08
HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial. Lancet Oncol (2009) 4.99
Polycomb group proteins: navigators of lineage pathways led astray in cancer. Nat Rev Cancer (2009) 4.40
Evolution in health and medicine Sackler colloquium: Stochastic epigenetic variation as a driving force of development, evolutionary adaptation, and disease. Proc Natl Acad Sci U S A (2009) 4.40
An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer. Genome Biol (2007) 4.33
A general framework for multiple testing dependence. Proc Natl Acad Sci U S A (2008) 4.27
Polycomb group proteins: multi-faceted regulators of somatic stem cells and cancer. Cell Stem Cell (2010) 4.18
Personalized epigenomic signatures that are stable over time and covary with body mass index. Sci Transl Med (2010) 3.81
An epigenetic signature in peripheral blood predicts active ovarian cancer. PLoS One (2009) 3.33
Widespread and tissue specific age-related DNA methylation changes in mice. Genome Res (2010) 2.99
Fundamental differences in cell cycle deregulation in human papillomavirus-positive and human papillomavirus-negative head/neck and cervical cancers. Cancer Res (2007) 2.93
Breast cancer methylomes establish an epigenomic foundation for metastasis. Sci Transl Med (2011) 2.33
Identification of copy number gain and overexpressed genes on chromosome arm 20q by an integrative genomic approach in cervical cancer: potential role in progression. Genes Chromosomes Cancer (2008) 2.29
PACK: Profile Analysis using Clustering and Kurtosis to find molecular classifiers in cancer. Bioinformatics (2006) 2.12
Gene expression differences associated with human papillomavirus status in head and neck squamous cell carcinoma. Clin Cancer Res (2006) 2.05
Taking the measure of the methylome. Nat Biotechnol (2010) 1.57
Testing for methylated PCDH10 or WT1 is superior to the HPV test in detecting severe neoplasms (CIN3 or greater) in the triage of ASC-US smear results. Am J Obstet Gynecol (2010) 1.56
Gene expression analysis of preinvasive and invasive cervical squamous cell carcinomas identifies HOXC10 as a key mediator of invasion. Cancer Res (2007) 1.53
ARTISTIC: a randomised trial of human papillomavirus (HPV) testing in primary cervical screening. Health Technol Assess (2009) 1.51
Identification of novel DNA methylation markers in cervical cancer. Int J Cancer (2008) 1.42
Genome-wide DNA methylation profiling. Wiley Interdiscip Rev Syst Biol Med (2010) 1.37
A comparison of HPV DNA testing and liquid based cytology over three rounds of primary cervical screening: extended follow up in the ARTISTIC trial. Eur J Cancer (2011) 1.34
Genome-wide methylation and expression differences in HPV(+) and HPV(-) squamous cell carcinoma cell lines are consistent with divergent mechanisms of carcinogenesis. Epigenetics (2011) 1.29
Assessment of gene promoter hypermethylation for detection of cervical neoplasia. Int J Cancer (2006) 1.23
Improved prognostic classification of breast cancer defined by antagonistic activation patterns of immune response pathway modules. BMC Cancer (2010) 1.22
Stress and the epigenetic landscape: a link to the pathobiology of human diseases? Nat Rev Genet (2010) 1.13
Adaptive index models for marker-based risk stratification. Biostatistics (2010) 1.07
DNA methylation in serum and tumors of cervical cancer patients. Clin Cancer Res (2004) 1.06
DNA methylation analysis in liquid-based cytology for cervical cancer screening. Int J Cancer (2009) 1.04
Genetic alterations during the progression of squamous cell carcinomas of the uterine cervix. Genes Chromosomes Cancer (1999) 0.97
Promoter hypermethylation of CDH13, DAPK1 and TWIST1 genes in precancerous and cancerous lesions of the uterine cervix. Pathol Res Pract (2010) 0.96
Methylation analysis of SFRP genes family in cervical adenocarcinoma. J Cancer Res Clin Oncol (2009) 0.87
The L1 major capsid protein of HPV16 differentially modulates APC trafficking according to the vaccination or natural infection context. Eur J Immunol (2010) 0.80
CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet (2006) 13.63
Epigenetic stem cell signature in cancer. Nat Genet (2006) 9.62
Age-dependent DNA methylation of genes that are suppressed in stem cells is a hallmark of cancer. Genome Res (2010) 6.03
HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial. Lancet Oncol (2009) 4.99
Evaluating the effects of imputation on the power, coverage, and cost efficiency of genome-wide SNP platforms. Am J Hum Genet (2008) 4.28
The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. Clin Cancer Res (2005) 4.02
Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature (2010) 4.01
A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nat Genet (2010) 3.86
FBXW7/hCDC4 is a general tumor suppressor in human cancer. Cancer Res (2007) 3.79
An epigenetic signature in peripheral blood predicts active ovarian cancer. PLoS One (2009) 3.33
Association of breast cancer DNA methylation profiles with hormone receptor status and response to tamoxifen. Cancer Res (2004) 3.23
Future acceptance of adolescent human papillomavirus vaccination: a survey of parental attitudes. Vaccine (2006) 3.18
Independent surrogate variable analysis to deconvolve confounding factors in large-scale microarray profiling studies. Bioinformatics (2011) 2.91
hCDC4 gene mutations in endometrial cancer. Cancer Res (2002) 2.36
DNA methylation in serum of breast cancer patients: an independent prognostic marker. Cancer Res (2003) 2.14
Breast cancer DNA methylation profiles in cancer cells and tumor stroma: association with HER-2/neu status in primary breast cancer. Cancer Res (2006) 1.99
Methylation changes in faecal DNA: a marker for colorectal cancer screening? Lancet (2004) 1.80
Body mass index, hormone replacement therapy, and endometrial cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev (2010) 1.75
Epigenotyping in peripheral blood cell DNA and breast cancer risk: a proof of principle study. PLoS One (2008) 1.75
DNA hypomethylation and ovarian cancer biology. Cancer Res (2004) 1.75
Genome-wide DNA methylation analysis of archival formalin-fixed paraffin-embedded tissue using the Illumina Infinium HumanMethylation27 BeadChip. Methods (2010) 1.71
Adjuvant radiotherapy for stage I endometrial cancer: an updated Cochrane systematic review and meta-analysis. J Natl Cancer Inst (2012) 1.68
Circulating tumor-specific DNA: a marker for monitoring efficacy of adjuvant therapy in cancer patients. Cancer Res (2005) 1.62
Hypomethylation and hypermethylation of DNA in Wilms tumors. Oncogene (2002) 1.59
DNA hypomethylation is prevalent even in low-grade breast cancers. Cancer Biol Ther (2004) 1.53
Immunological responses in women with human papillomavirus type 16 (HPV-16)-associated anogenital intraepithelial neoplasia induced by heterologous prime-boost HPV-16 oncogene vaccination. Clin Cancer Res (2004) 1.51
Differential variability improves the identification of cancer risk markers in DNA methylation studies profiling precursor cancer lesions. Bioinformatics (2012) 1.51
Human papillomavirus and cervical cancer. Lancet (2013) 1.48
Mutation of hCDC4 leads to cell cycle deregulation of cyclin E in cancer. Cancer Res (2004) 1.45
HOXA11 DNA methylation--a novel prognostic biomarker in ovarian cancer. Int J Cancer (2008) 1.44
A semi-qualitative study of attitudes to vaccinating adolescents against human papillomavirus without parental consent. BMC Public Health (2007) 1.44
Induction of the antimicrobial peptide CRAMP in the blood-brain barrier and meninges after meningococcal infection. Infect Immun (2006) 1.41
Informing adolescents about human papillomavirus vaccination: what will parents allow? Vaccine (2008) 1.37
A comparison of HPV DNA testing and liquid based cytology over three rounds of primary cervical screening: extended follow up in the ARTISTIC trial. Eur J Cancer (2011) 1.34
cDNA microarray analysis of genes associated with ERBB2 (HER2/neu) overexpression in human mammary luminal epithelial cells. Oncogene (2003) 1.34
The dynamics and prognostic potential of DNA methylation changes at stem cell gene loci in women's cancer. PLoS Genet (2012) 1.33
A comparison of feature selection and classification methods in DNA methylation studies using the Illumina Infinium platform. BMC Bioinformatics (2012) 1.26
Immunological and clinical responses in women with vulval intraepithelial neoplasia vaccinated with a vaccinia virus encoding human papillomavirus 16/18 oncoproteins. Cancer Res (2003) 1.24
Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer. Clin Cancer Res (2002) 1.22
Recruitment of newly diagnosed ovarian cancer patients proved challenging in a multicentre biobanking study. J Clin Epidemiol (2010) 1.18
Role of miR-34a as a suppressor of L1CAM in endometrial carcinoma. Oncotarget (2014) 1.18
Adjuvant radiotherapy for stage I endometrial cancer. Cochrane Database Syst Rev (2012) 1.16
Cellular network entropy as the energy potential in Waddington's differentiation landscape. Sci Rep (2013) 1.12
Therapy of human papillomavirus-related disease. Vaccine (2012) 1.11
Cyclin-dependent kinase subunit (Cks) 1 or Cks2 overexpression overrides the DNA damage response barrier triggered by activated oncoproteins. Proc Natl Acad Sci U S A (2011) 1.11
Role of DNA methylation and epigenetic silencing of HAND2 in endometrial cancer development. PLoS Med (2013) 1.10
Body mass index does not influence post-treatment survival in early stage endometrial cancer: results from the MRC ASTEC trial. Eur J Cancer (2011) 1.10
Methylation status of the Ep-CAM promoter region in human breast cancer cell lines and breast cancer tissue. Cancer Lett (2006) 1.07
DNA methylation in serum and tumors of cervical cancer patients. Clin Cancer Res (2004) 1.06
Prognostic DNA methylation marker in serum of cancer patients. Ann N Y Acad Sci (2004) 1.06
Methylated DNA as a possible screening marker for neoplastic disease in several body fluids. Expert Rev Mol Diagn (2003) 1.06
Methylation status and expression of human telomerase reverse transcriptase in ovarian and cervical cancer. Gynecol Oncol (2004) 1.06
Clinical and immunologic results of a phase II trial of sequential imiquimod and photodynamic therapy for vulval intraepithelial neoplasia. Clin Cancer Res (2008) 1.05
DNA methylation analysis in liquid-based cytology for cervical cancer screening. Int J Cancer (2009) 1.04
Attenuation of cell adhesion in lymphocytes is regulated by CYTIP, a protein which mediates signal complex sequestration. EMBO J (2003) 1.04
Interferon-gamma expression is an independent prognostic factor in ovarian cancer. Am J Obstet Gynecol (2004) 1.03
The ScpC protease of Streptococcus pyogenes affects the outcome of sepsis in a murine model. Infect Immun (2008) 1.02
SFRP2 methylation in fecal DNA--a marker for colorectal polyps. Int J Colorectal Dis (2007) 1.02
Inactivation of FBXW7/hCDC4-β expression by promoter hypermethylation is associated with favorable prognosis in primary breast cancer. Breast Cancer Res (2010) 1.01
The Impact of Sample Storage Time on Estimates of Association in Biomarker Discovery Studies. J Clin Bioinforma (2011) 1.00
Long non-coding RNAs as targets for cytosine methylation. RNA Biol (2013) 1.00
Underlying mechanisms of ovarian cancer risk reduction after tubal ligation. Acta Obstet Gynecol Scand (2011) 0.99
Methylated DNA collected by tampons--a new tool to detect endometrial cancer. Cancer Epidemiol Biomarkers Prev (2004) 0.99
Cyclin E dysregulation and chromosomal instability in endometrial cancer. Oncogene (2004) 0.99
CDK-mediated activation of the SCF(FBXO) (28) ubiquitin ligase promotes MYC-driven transcription and tumourigenesis and predicts poor survival in breast cancer. EMBO Mol Med (2013) 0.99
Analysis of methylated genes in peritoneal fluids of ovarian cancer patients: a new prognostic tool. Clin Chem (2004) 0.98
Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer. Cochrane Database Syst Rev (2012) 0.98
Loss of imprinting and aberrant methylation of IGF2 in placentas from pregnancies complicated with fetal growth restriction. Int J Mol Med (2011) 0.96
Analysis of aberrant DNA methylation and human papillomavirus DNA in cervicovaginal specimens to detect invasive cervical cancer and its precursors. Clin Cancer Res (2004) 0.96
A report on the current status of European research on the use of human papillomavirus testing for primary cervical cancer screening. Int J Cancer (2006) 0.95
CDH1 and CDH13 methylation in serum is an independent prognostic marker in cervical cancer patients. Int J Cancer (2004) 0.95
Distinctive topology of age-associated epigenetic drift in the human interactome. Proc Natl Acad Sci U S A (2013) 0.94
Toll-like receptor 9 expression in breast and ovarian cancer is associated with poorly differentiated tumors. Cancer Sci (2010) 0.92
Detection of low molecular weight derivatives of cyclin E1 is a function of cyclin E1 protein levels in breast cancer. Cancer Res (2006) 0.92
DNA methylation changes in sera of women in early pregnancy are similar to those in advanced breast cancer patients. Clin Chem (2004) 0.91
Specific HIV protease inhibitors inhibit the ability of HPV16 E6 to degrade p53 and selectively kill E6-dependent cervical carcinoma cells in vitro. Antivir Ther (2006) 0.91